Fms-like tyrosine kinase-3 (FLT3) mutations occur in approximately 30% of acute myeloid
leukemia (AML) cases, suggesting FLT3 as an attractive target for AML treatment. Early …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …

FLT3 mutations are one of the most common genetic alterations in acute myeloid leukemia
(AML) and are identified in approximately one-third of newly diagnosed patients. Aberrant …

Introduction: Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur at
high frequency in acute myeloid leukemia (AML), being detected in> 30% of patients at …

Acute myeloid leukemia (AML) is a cancer of the myeloid lineage of blood cells. Although
significant progress has been made in treating many types of cancers during recent years …

The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation,
survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have …

Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are detected in approximately one-
third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the …

Introduction: The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias.
Mutations involving FLT3 are among the most common molecular abnormalities in acute …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene arise in 25-30% of all acute myeloid
leukemia (AML) patients. These mutations lead to constitutive activation of the protein …

Fms-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid
leukemia (AML). Modern targeting of FLT3 with inhibitors has improved clinical outcomes …